EUVIMEDEUVIMED entdecken
Open Access

Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: A Single-institution Retrospective Study

Atsuto Katano, Hideomi Yamashita

Cancer Diagnosis & Prognosis · 01.11.2026 · 6 (6) · 961-968

DOI: 10.21873/cdp.10598 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 01.11.2026. Verfasst von Atsuto Katano und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The University of Tokyo Hospital, Tokyo, Japan. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim: The aim of the present study was to evaluate clinical outcomes of radiotherapy-based treatment in patients with previously untreated cervical esophageal squamous cell carcinoma at a single institution. Patients and Methods: We retrospectively analyzed consecutive patients who received curative-intent radiotherapy for cervical esophageal cancer between July 2012 and October 2025. Eligible patients had histologically confirmed squamous cell carcinoma and no distant metastasis, except for supraclavicular lymph nodes included within the radiation field. All patients received concurrent platinum-based chemotherapy. Overall (OS) and progression-free (PFS) survival were estimated using the Kaplan–Meier method.

Results

A total of 33 patients were included. The median age was 64 years (range=45-83 years), and most patients had advanced disease (T4b: 51.5%). The median follow-up was 20.3 months. The median OS and PFS were 58.2 and 12.1 months, respectively. The 1-, 2-, and 3-year OS rates were 86.2%, 60.1%, and 55.8%, respectively, while the corresponding PFS rates were 51.3%, 37.3%, and 37.3%. Patients with stage I-II disease had significantly better OS than those with stage III-IVA/B disease (2-year OS: 100% vs. 51.2%, p=0.0383), although the difference in PFS did not reach statistical significance. Disease progression occurred in 21 patients (63.6%); among them, 15 (71.4%) developed locoregional-only recurrence.

Conclusion

Radiotherapy-based treatment for cervical esophageal squamous cell carcinoma achieved favorable OS despite a high proportion of patients with advanced-stage disease. However, disease progression remained frequent, particularly locoregional recurrence, underscoring the need for optimized multimodal treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

Esophageal neoplasmschemoradiotherapydisease progressionprognosisradiotherapysquamous cell carcinomasurvival analysistreatment outcome

Autor:innen und Institutionen

  • Department of Radiology, The University of Tokyo Hospital, Tokyo, Japan.

Zitieren

APA

Katano, A., & Yamashita, H. (2026). Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: A Single-institution Retrospective Study. Cancer Diagnosis & Prognosis, 6(6), 961-968. https://doi.org/10.21873/cdp.10598

Vancouver

Katano A, Yamashita H. Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: A Single-institution Retrospective Study. Cancer Diagnosis & Prognosis. 2026;6(6):961-968. doi:10.21873/cdp.10598

BibTeX
@article{Katano2026,
  author = {Katano, Atsuto and Yamashita, Hideomi},
  title = {Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: A Single-institution Retrospective Study},
  journal = {Cancer Diagnosis & Prognosis},
  year = {2026},
  volume = {6},
  number = {6},
  pages = {961--968},
  doi = {10.21873/cdp.10598}
}
Kostenlos starten →